Matthias Preusser
 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (October 2017) |
 | A major contributor to this article appears to have a close connection with its subject. (October 2017) |
Matthias Preusser | |
|---|---|
 | |
| Born | 29 October 1976 |
| Nationality | Austrian |
| Known for | neurooncology, Molecular medicine targets, biomarkers. |
| Awards | Cardinal-Innitzer-Price (2009), Sibylle Assmus Price for Neuro-Oncology (2009), Advancement award of the city of Vienna (2010, 2013) |
| Scientific career | |
| Fields | internal medicine, hematology, medical oncology |
| Institutions | Medical University of Vienna |
Matthias Preusser (born 29 October 1976, Mödling) is an Austrian oncologist and Professor of Medical Oncology at the Medical University of Vienna. He is known for his work on neurooncology, Molecular Therapy targets and biomarkers and immunotherapy of cancer.
Biography
Matthias Preusser studied medicine at the Medical University of Vienna, received his Medical Doctor (M.D.) degree in 2003 and holds specialist diplomas for internal medicine, hematology and medical oncology. He achieved habilitation in the field of Experimental Oncology 2009 with the thesis Analysis of Biomarkers in Brain Tumours and in the field of Internal Medicine 2016 with the thesis Personalized Therapy of Cancer. From 2009 he spent stays abroad at the German Cancer Research Center, Heidelberg and at the Memorial Sloan-Kettering Cancer Center, New York. On October 1st 2018 Preusser was appointed as full professor of medical oncology at the Department of Medicine I, Clinical Division of Oncology at the Medical University of Vienna. He also serves as coordinator of the brain tumor unit of the Comprehensive Cancer Center – Central Nervous System (CCC-CNS).
Scientific contributions
Preusser's scientific work deals with the identification of molecular changes with prognostic and therapeutic relevance in brain tumors. His investigations on the significance of the MGMT gene[1] (O-6-methylguanine-DNA methyltransferase), the IDH gene[2] (glioblastoma multiforme) and the BRAF gene[3] and the immunophenotype inlcuing the role of PD-L1 in gliomas and brain metastases are highly cited and he is co-author of the current WHO brain tumor classification, which is considered an international standard reference.[4] The oncologist leads several international clinical studies including a randomised therapy trial on high grade meningioma.
Academic memberships
- European Society of Medical Oncology ESMO
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Association of Neurooncology (EANO)
- Society of Austrian Neurooncology (SANO) (cofounder and first secretary)
- Österreichische Gesellschaft für Hämatologie und Medizinische Onkologie (ÖGHO)
- Central European Cooperative Oncology Group (CECOG)
Honors and awards
- 2008 Medical University of Vienna Researcher of the month
- 2009 Cardinal-Innitzer-Price (advancement award)[5]
- 2009 Sibylle Assmus Price for Neuro-Oncology, Heidelberg[6]
- 2011 EANO Fellowship Grant[7]
- 2010 und 2013 Advancement award of the city of Vienna[8]
Publications
References
- ^ M. Preusser, Charles R. Janzer, J. Felsberg, G. Reifenberger, M. F. Hamou, A. C. Diserens, R. Stupp, T. Gorlia, C. Marosi, H. Heinzl, J. A. Hainfellner, M. Hegi: Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008 Oct;18(4), S. 520–532. doi:10.1111/j.1750-3639.2008.00153.x.
- ^ M. Preusser, A. Wöhrer, S. Stary, R. Höftberger, B. Streubel, J. A. Hainfellner: Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol. 2011 Aug;70(8), S. 715–723. doi:10.1097/NEN.0b013e31822713f0.
- ^ D. Capper, A. S. Berghoff, M. Magerle, A. Ilhan, A. Wöhrer, M. Hackl, J. Pichler, S. Pusch, J. Meyer, A. Habel, P. Petzelbauer, P. Birner, A. von Deimling, M. Preusser: Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012 Feb;123(2), S. 223–233. doi:10.1007/s00401-011-0887-y.
- ^ WHO brain tumor classification
- ^ onkologie-wien.at
- ^ stiftung-sibylle-assmus.de Archived 7 December 2013 at the Wayback Machine
- ^ docstoc.com
- ^ meduniwien.ac.at
External links
- ESMO 2012 Kongress. Melanoma. Matthias Preusser, Comprehensivce Cancer Center Medical University of Vienna
- Matthias Preusser
